Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors.

BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

We played a major role in characterising the BRAF gene and its role in cancer ... Their research increased our knowledge of the pathway – known as the RAS/RAF/MEK/ERK pathway – and its role in cancer, ...

As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type tumors. We are now investigating the biochemical actions and anti-tumor ...

Regorafenib significantly inhibits TAS102-induced angiogenesis and microvessel density in xenografted tumors, as well as inhibits TAS102-induced ERK1/2 activation regardless of RAS or BRAF status ...

BRAF, and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS/MAPK pathway inhibition. In contrast to currently available MEK-only inhibitors ...